Read More

Anavex Life Sciences Announces Late-Breaking Presentation Of Phase 2b/3 Data of Oral ANAVEX 2-73 (blarcamesine) For Early Alzheimer’s Disease At Upcoming Clinical Trials On Alzheimer’s Disease (CTAD) Congress 2022

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and

AVXL